Dr. David Zaccardelli is an accomplished biopharmaceutical executive with more than 20 years of experience leading companies through transformational growth, including leading companies from clinical to commercial stage. He most recently served as President and Chief Executive Officer of Verona
Samuel J. Reich currently serves as Chief Executive Officer of SAB Biotherapeutics. He was elected CEO of SAB BIO in January 2024. Previously, he served as Executive Chairman of SAB’s board of directors following SAB’s business combination with Big Cypress Acquisition Corp in October 2021 until
Eddie J. Sullivan, PhD, is our co-founder and president since 2014. Dr. Sullivan has served in biopharma leadership positions for more than 25 years. Prior to joining us, he held the CEO role or other leadership roles in our predecessor entities, including CEO of Hematech, a subsidiary of Kyowa
Katie Ellias joined SAB's Board of Directors in November 2023, bringing more than twenty years of health care and investment experience to SAB. Ms. Ellias is a healthcare investor, board member, advisor, and operator with more than 20 years of experience building and investing in healthcare and
CEO, AMI Expeditionary Healthcare and Rear Admiral (Ret.)
Rear Admiral (RADM), retired, Scott Giberson joined the SAB board of directors in July 2022. He is currently the Chief Executive Officer of AMI Expeditionary Healthcare, a private global healthcare solutions company where he fosters global client relations at the highest levels.
Dr. Rita Jain is a rheumatologist who brings more than two decades of leadership experience in biopharmaceutical development, clinical strategy, and regulatory affairs across multiple therapeutic areas, including immunology, inflammation, nephrology, and rare diseases.
David Link, MBA, has served as a member of our board of directors since 2018 and is currently Vice Chairman. Mr. Link is the former Executive Vice President and Chief Strategy Officer at Sanford Health with more than three decades of experience in strategy, planning and financial operations.
Erick Lucera joined the SAB board of directors in April 2023, bringing thirty years of financial, operational, and investment experience in the biotechnology and medical device industry. Currently, Mr. Lucera serves as Chief Financial Officer of Dyne Therapeutics.
Andrew Moin joined the SAB Board of Directors in October 2023, bringing more than 15 years of expertise across investment management and law, and is a passionate supporter of the type 1 diabetes community. Mr. Moin is currently a Partner and Analyst at Sessa Capital, a New York based investment
Dr. William J. Polvino, MD, has served as a member of our board of directors since 2019, after having served as our business advisor for several years. Dr. Polvino is pharmaceutical entrepreneur with more than 25 years of experience in the healthcare arena.
Dr. Jay S. Skyler, M.D., MACP, FRCP joined the Board in May 2024. He is a Professor of Medicine, Pediatrics and Psychology and Chief Academic Officer of the Diabetes Research Institute at the University of Miami in Florida, where he has been employed since 1976. Dr.
